Actively Recruiting
Registry Platform Gastric/Esophageal Cancer (SAPHIR)
Led by iOMEDICO AG · Updated on 2026-01-28
1900
Participants Needed
1
Research Sites
473 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.
CONDITIONS
Official Title
Registry Platform Gastric/Esophageal Cancer (SAPHIR)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically proven stage IV (metastatic) esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma
- Planned palliative systemic first-line therapy
- Age 18 years or older
- Signed informed consent before first therapy cycle if answering questionnaires or within 4 weeks after therapy start if not answering questionnaires
You will not qualify if you...
- No systemic therapy planned for esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Multiple sites, Gemany
Multiple Locations, Germany
Actively Recruiting
Research Team
A
Adrian Binninger
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here